Canadian Cancer Trials Group Bulletins

Trial Management Group


Investigational Medicinal Product (IMP)

Investigational Medicinal Product (IMP) for specific Canadian Cancer Trials Group trials* is currently distributed by Investigational Drug Research Services (IDRS) located at Kingston General Hospital. This service will cease deliveries on or before December 31st, 2010 and distribution services for all trials currently using IDRS will be outsourced to another vendor effective on or before January 1st 2011.

The transition of services will occur over the next two months. Each trial will be transferred to a vendor that has met our needs with respect to quality and price for IMP distribution in oncology research studies. Every effort is being made to ensure a seamless transition of drug supply.
Trials for which IMP distribution is handled directly by an industry partner, and Intergroup-led studies for which distribution is done by the Pharmaceutical Management Branch (PMB) (US), are unaffected by this change.

Individual trial teams will notify participating sites of specific details for new drug orders. Please continue with current processes until contacted with individual trial changes.

Andrew Dowker (IMP coordinator) is also available for centres with general questions; inquires can be directed to him at adowker@ctg.queensu.ca.

*Trials to be transferred to an alternate vendor include: IND.187, 190, 192, 195, 196, 200, CLC.1, CL.3, CRC.5, MAC.7, MAP.3, MY.10, CO.20, HN.6, LY.12, BR.26, BR.29.